Adamed Pharma European expansion

Polish pharmaceutical and biotechnology company Adamed Pharma has undertaken significant expansion efforts across Europe through strategic acquisitions and investments.

In July 2026, the company finalized an investment of 22 million euros to increase its stake in the Italian firm Ecupharma from 25% to 85%. This move aims to double Adamed’s Italian revenues to 87 million euros within five years and expand its product portfolio to over 220 references, focusing on therapeutic areas such as urology, neurology, psychiatry, and cardiology.

Additionally, Adamed Pharma announced a strategic investment plan exceeding 100 million euros for its manufacturing plant in Riells i Viabrea, Spain, which it acquired from Sanofi. Scheduled to continue through 2034, the investment focuses on modernizing digital infrastructure, upgrading equipment, and automating logistics. The company intends to triple the plant’s annual production capacity from 3 billion to 10 billion tablets by 2029, utilizing the site as a strategic hub to strengthen the European medicine supply chain.